Dossier assessment

Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-118
Last updated

Report documents

  1. Extract of dossier assessment

    Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 691 kB, EN, not accessible
  2. Dossier assessment

    Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 828 kB, DE, not accessible

Dossier assessment

Indication:

First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation

Result of dossier assessment:

PD-L1 expression (TPS) of at least 50 percent: added benefit not proven.

PD-L1 expression (TPS) below 50 percent: non-squamous histology: indication of added benefit; extent “non-quantifiable". Squamous histology: added benefit not proven.

Additional information

Federal Joint Committee (G-BA)

2021.06.04 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-118
Commission
Commission awarded on 14.12.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-11
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-53
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A18-40
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-29
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A17-27
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-24
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-76
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-35
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V

    Project no.
    A16-25
    Last updated

    Status: Commission completed

  10. Dossier assessment

    Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-24
    Last updated

    Status: Commission completed

  11. Dossier assessment

    Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A15-32
    Last updated

    Status: Commission completed

  12. Dossier assessment

    Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A15-27
    Last updated

    Status: Commission completed

  13. Addendum

    Nivolumab (NSCLC) - Addendum to Commission A20-118

    Project no.
    A21-57
    Last updated

    Status: Commission completed

  14. Dossier assessment

    Nivolumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-99
    Last updated

    Status: Commission completed

  15. Dossier assessment

    Nivolumab (malignant pleural mesothelioma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-89
    Last updated

    Status: Commission completed

  16. Dossier assessment

    Nivolumab (oesophageal or gastro-oesophageal junction cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-108
    Last updated

    Status: Commission completed

  17. Dossier assessment

    Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A21-39
    Last updated

    Status: Commission completed

  18. Dossier assessment

    Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-59
    Last updated

    Status: Commission completed

  19. Dossier assessment

    Nivolumab (oesophageal or gastro-oesophageal junction cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-88
    Last updated

    Status: Commission completed

  20. Dossier assessment

    Nivolumab (NSCLC, perioperative) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-81
    Last updated

    Status: Commission completed

  21. Dossier assessment

    Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A25-154
    Last updated

    Status: Commission completed

  22. Dossier assessment

    Nivolumab (hepatocellular carcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-79
    Last updated

    Status: Commission completed

  23. Dossier assessment

    Nivolumab (melanoma in adolescents, adjuvant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-59
    Last updated

    Status: Commission completed

  24. Dossier assessment

    Nivolumab (unresectable or metastatic urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-70
    Last updated

    Status: Commission completed

  25. Dossier assessment

    Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-58
    Last updated

    Status: Commission completed

  26. Dossier assessment

    Nivolumab (oesophageal squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-54
    Last updated

    Status: Commission completed

  27. Dossier assessment

    Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-74
    Last updated

    Status: Commission completed

  28. Dossier assessment

    Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-55
    Last updated

    Status: Commission completed

  29. Dossier assessment

    Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-53
    Last updated

    Status: Commission completed

  30. Dossier assessment

    Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-94
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form